¶ AAIC 2026: Clinical Trials and Drug Development
Conference: AAIC 2026 | Dates: July 12-15, 2026 | Location: Excel London, UK
AAIC 2026 features comprehensive coverage of clinical trial results and drug development programs for Alzheimer's disease and related dementias. This page captures Phase 2/3 trial results, novel therapeutic compounds, and emerging treatment strategies presented at the conference.
- CLARITY-AD Open Label Extension: Long-term effectiveness data
- ARIA management protocols: Real-world experience
- Biomarker correlates: Plasma p-tau217 as treatment response marker
- TRAILBLAZER-ALZ 3: Preclinical AD prevention trial updates
- TRAILBLAZER-ALZ 2 OLE: Extended follow-up data
- Tau burden stratification: Impact on treatment response
- GRADUATE trials: Complete results and analyses
- Lessons learned: Dose optimization and plaque clearance
- RNIC (SPRING): Anti-tau antibody in Phase 2
- J&J programs: Multiple tau-targeted approaches
- AC Immune: Novel tau vaccine candidates
- Methylthioninium chloride (MTC): Phase 3 results
- Small molecule modulators: Clinical development status
- Exenatide: Phase 2 cognitive outcomes
- Semaglutide: Phase 3 EMERALD program
- Tirzepatide: Dual GIP/GLP-1 in AD
- Cytochrome c oxidase modulators: Phase 1/2 results
- NAD+ precursors: NIC5-15 and NMN trials
- Antioxidant approaches: Mitochondrial-targeted antioxidants
| Compound |
Target |
Phase |
Company |
| AL108 (PNQX) |
PDE9 inhibitor |
Phase 2 |
Pfizer |
| ACD-855 |
Tau aggregation |
Phase 1 |
Acumen |
| JNJ-63733657 |
Tau antibody |
Phase 2 |
J&J |
| LY3374289 |
Anti-Aβ antibody |
Phase 1 |
Eli Lilly |
- AAV-mediated gene delivery: BDNF, NGF delivery
- Antisense oligonucleotides: APP and tau reduction
- CRISPR-based approaches: Emerging preclinical programs
- Stem cell approaches: MSC transplantation trials
- Microglial modulation: Targeted cell therapies
- Biologic delivery: Novel delivery mechanisms
AAIC 2026 highlights the shift toward combination therapies:
- Anti-amyloid + anti-tau: Simultaneous pathology targeting
- Anti-amyloid + neuroprotective: Complementary mechanisms
- Disease-modifying + symptomatic: Comprehensive treatment
- Plasma biomarkers: p-tau217, p-tau181, GFAP
- Tau PET: Patient stratification for anti-tau trials
- Genetic stratification: APOE and polygenic risk scores
- Autosomal dominant AD: DIAN-TU trial updates
- Down syndrome: Alzheimer's prevention in trisomy 21
- Early-onset AD: Targeted therapeutic approaches
¶ Priority Candidates
| Drug |
Original Indication |
AD Target |
Phase |
| Metformin |
Diabetes |
Insulin sensitization |
Phase 3 |
| Losartan |
Hypertension |
Vascular protection |
Phase 2 |
| Atorvastatin |
Hyperlipidemia |
Cholesterol modulation |
Phase 3 |
| Valacyclovir |
Herpes |
Antiviral approach |
Phase 2 |
- SPRINT-MIND: Blood pressure and cognitive outcomes
- EXERT: Exercise in preclinical AD
- MIND Diet: Nutritional intervention results
- Smartphone-based cognitive assessments
- Remote monitoring technologies
- Digital biomarker collection
- Platform trials for AD
- Master protocols
- Bayesian approaches
- Real-world evidence generation
- Registry-based trials
- Embedded trials
- Major Phase 3 trial results
- Novel mechanism presentations
- First-in-human data
- "Clinical Trial Design in the Era of Biomarkers"
- "Combination Therapy: Rationale and Evidence"
- "Repurposing Successes and Failures"
- AAIC 2026 Conference
- AAIC 2026: Therapeutic Approaches
- AAIC 2026: Prevention Trials
- AAIC 2026: Biomarker-Guided Clinical Trials
- Clinical Trials Index